로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Integrin alpha E beta 7

Integrin alpha E beta 7

요약

Name:Integrin alpha-E/beta-7
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 3 Clinical

제품 리스트 구매

일부의 생물활성 데이터

IT7-H52W7-SPR
 Integrin alpha E beta 7 SPR

Human ITGAE&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W7) immobilized on CM5 Chip can bind Human E-Cadherin, Fc Tag, premium grade (Cat. No. ECD-H5250) with an affinity constant of 0.148 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

IT7-C52W3-ELISA
 Integrin alpha E beta 7 ELISA

Immobilized Cynomolgus ITGAE&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-C52W3) at 5 μg/mL (100 μL/well) can bind Human E-Cadherin, Fc Tag, premium grade (Cat. No. ECD-H5250) with a linear range of 0.078-1.25 μg/mL (QC tested).

Synonym Name

Integrin alpha E beta 7,ITGAE&ITGB7,HML-1,CD103,ITGAE&B7

Background

Integrin alpha E beta 7 consist of two major subunits: Integrin alpha E (ITGAE) also known as CD103 (cluster of differentiation 103) and Integrin beta-7 is an integrin protein that in humans is encoded by the ITGB7 gene. Integrin alpha E beta 7 (CD103) is expressed mainly by cells of the T lymphocyte lineage within mucosal tissues. This is a strikingly narrow pattern of expression compared with that of other integrins. Lymphocytes expressing alpha E beta 7 are abundant in the gut and comprise a major part of the total T cell complement of the body. The effectiveness of lung transplantation is marred by the relatively high incidence of rejection. The lung normally contains a large population of lymphocytes in contact with the airway epithelium, a proportion of which expresses the mucosal integrin, alpha(E)(CD103)beta(7). This integrin is not a homing receptor, but is thought to retain lymphocytes at the epithelial surface.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Etrolizumab PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 Phase 3 Clinical Genentech Inc Colitis, Ulcerative; Crohn Disease Details
Etrolizumab PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 Phase 3 Clinical Genentech Inc Colitis, Ulcerative; Crohn Disease Details

This web search service is supported by Google Inc.

totop